Management of advanced renal cell carcinoma remains a persistent clinical challenge with high morbidity and mortality for a large proportion of patients. Until recently, available medical ...

Renal cell carcinoma (RCC) refers to a heterogenous group of cancers that originate in the proximal convoluted tubule of the kidney. The three most common forms of RCC are clear cell RCC ...

A biologics license application for TLX250-CDx has been submitted to the FDA, as supported by the phase 3 ZIRCON trial ...

Renal cell carcinoma usually presents as a solid mass; however, in 10–22% of cases, it appears as a unilocular or multilocular cystic mass on imaging studies. Four mechanisms have been described ...

such as an X-ray or MRI. There are three main types of kidney cancers: renal cell carcinoma, transitional cell carcinoma, and ...

Medically reviewed by Gagandeep Brar, MD Hypernephroma (also called renal cell adenocarcinoma or clear-cell carcinoma of the ...

Manmeet Ahluwalia, MD, MBA, FASCO, discusses the prevalence of brain metastases in patients with primary renal cell carcinoma.

TLX250-CDx is an investigational PET 3 drug product for the non-invasive diagnosis and characterization of clear cell renal cell carcinoma (ccRCC), the most common and aggressive form of kidney cancer ...

Telix submits BLA to US FDA for TLX250-CDx kidney cancer imaging: Melbourne, Australia Tuesday, December 31, 2024, 15:00 Hrs [IST] Telix, a biopharmaceutical company focused on th ...

A Biologics License Application has been submitted to the FDA for treatment with the kidney cancer imaging PET drug product, Zircaix®.